Fig 3. Immunoblotting analyses showing that the proteasome catalytic subunit β5, a primary target of carfilzomib remains unchanged in post-treatment tumor tissue lysates collected from the xenograft mice that received different treatments.

(CFZ-CD: cyclodextrin-based carfilzomib formulation; CFZ-PM: polymeric micelle formulation containing carfilzomib) The tumor tissues were collected 48 h after the last injection of the respective treatments.